What is the clinical evidence to support off-label rapamycin therapy in healthy adults?

Authors

Jacob M. Hands, The George Washington University School of Medicine and Health Sciences, Washington DC, DC 20037, USA.
Michael S. Lustgarten, Metabolism and Basic Biology of Aging, Jean Mayer USDA Human Nutrition Research Center on Aging (HNRCA) at Tufts University, Boston, MA 02111, USA.
Leigh A. Frame, The George Washington University School of Medicine and Health Sciences, Washington DC, DC 20037, USA.
Bradley Rosen, mTOR Medicine Practitioner, Los Angeles, CA 90212, USA.

Document Type

Journal Article

Publication Date

8-7-2025

Journal

Aging

Volume

17

DOI

10.18632/aging.206300

Keywords

aging; mTOR; rapamycin

Abstract

Low dose rapamycin therapy has been proposed as a longevity candidate in healthy aging adults. We present a review of the evidence for low dose rapamycin and rapalog therapies in healthy human adults and model the findings of one cohort study using the PhenoAge model. Despite the preclinical evidence supporting the use of sirolimus to enhance mean and maximal lifespan, the data in humans have yet to establish that rapamycin, or its analogues, is a proven seno-therapeutic that can delay aging in healthy older adults. Rapamycin and rapalogs warrant further study with larger cohorts to better establish their contribution to human aging.

APA Citation

Hands, Jacob M.; Lustgarten, Michael S.; Frame, Leigh A.; and Rosen, Bradley, "What is the clinical evidence to support off-label rapamycin therapy in healthy adults?" (2025). GW Authored Works. Paper 7804.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/7804

Department

School of Medicine and Health Sciences Student Works